MHRA - Building resilience into clinical trial design and conduct during the pandemic

This guidance follows on from that published on managing clinical trials during COVID-19 and has been developed to assist those involved in running clinical trials of medicines. This will avoid disruptions as a result of the continuing pandemic and will support appropriate incorporation of the available flexibilities into normal practice for the benefit of trial participants. It is relevant to those involved with ongoing studies, those wishing to restart trials that have been paused or temporarily halted, and those wishing to start new studies.

Click here for more information. 

We have placed cookies on your computer to help make this website better. For more information please click here

By continuing to use this site or closing this panel, we'll assume you're OK to continue. You can view our full privacy policy here